Trendingup
BTC on Huobi holding support - What's next?Hello everyone! 👋
Inside last week's 13% range, three bearish daily candles were able to take the price 10% lower to close the week at $8,715.
This level is approximately the same as the previous week's close. Will it hold as support?
From @tradeprophet on Twitter via CoinMarketCal.com
Risk Reminder:
1. Trading in digital assets comes with high risks due to huge price fluctuations. Users should be fully aware of the risks associated with digital asset trading and make prudent trading decisions.
2. Huobi Global’s announcements and information do not constitute investment advice, and Huobi will not bear responsibility or provide compensation for direct or indirect losses arising from trading decisions whilst relying on this information.
GOLD looking bullish !GOLD ($GLD)
Currently in a bullish trend and displaying consolidating volatility which means a big move in either direction. Expectations of continuing in a bullish trend in a setup resembling something we currently have is usually more probable.
I will be looking to enter the trade at $161.10. Intermediate target at $165.29 and full target at $166.83. Potential to overperform as there is a “key level of significance” at $174 as your next major resistance. Stop Loss set at $158.10. On Balance Volume also looks strong for the bullish scenario on this chart as well as for $XAU/USD while doing a 360-degree analysis.
MJ has been strong as consumers load up on cannabisIt's difficult to pick which cannabis stocks will survive and which will thrive, but the ETFMG Alternative Harvest ETF (MJ) provides a selection of the major players in this young industry. The industry has suffered bumps and grinds, but is due for a rebound, consolidation and growth.
$LXRX Fill The Gap And Go Or Will It Breakdown?LXRX is a penny stock that has performed well over the last few weeks but looking at the chart, shares are trading within the gap zone. Volume this week compared to previous weeks is lower. Is that a concern or just a slow week?
"Shares of LXRX stock have been on a tear for around a month. This was ever since terminating its partnership agreement with Sanofi. The termination gave Lexicon full control over its diabetes product Zynquista and in addition to that, Sanofi is going to pay the company as much as $260 million as a parting shot...The company will be conducting poster presentations of its XERMELO therapy this week at the North American Neuroendocrine Tumor Society Annual Multidisciplinary NET Medical Symposium." *
About LXRX
Lexicon Pharmaceuticals is a biopharmaceutical company that uses mouse genetics to discover the function of genes and find promising drug targets. Lexicon then designs and develops drugs for these targets, which cover a broad spectrum of therapeutic areas. Following a restructuring in January 2014, Lexicon focused efforts on two drugs: sotagliflozin in diabetes, which is partnered with Sanofi, and Xermelo (telotristat etiprate) in carcinoid syndrome, which is partnered with Ipsen outside the U.S. Early-stage programs include SGLT1 inhibitor LX2761 and neuropathic pain drug LX9211.
*SOURCE: Are Penny Stocks Worth It? 3 Up Big In October
ANTM = REVERSAL UPWARDS HAPPENING / DETAILED REPORT / TP: $294 ANTM has established support at $284 and if you look at the graph. Each green line shows a support level. The first resistance level is at $294. If it breaks the resistance level then it will easily pass $300. The technical analysis pattern is a BULL FLAG and is trending upwards. It's most recent support level is at $284. Volume is staring to increase which makes the indicator stronger. The MACD indicator is about to crossover leading an indication of upwards momentum.
Fundamental Analysis:
Liabilities in 2017 are 44,037 (in millions) while in 2018 are 43,030 (in millions). They are decreasing liabilities and increasing total assets which are 70,540 (In millions) in 2017 while in 2018 are 71,571 (In millions). At least in the balance sheet they are doing a decent job at maintaining profitable which can be seen the number of times they have beat earnings. Cash flow are growing steady which is another indication in terms of fundamental analysis this company will continue to grow. Short Interest is 1.72% which is good for the bullish investors. The Beta is 0.7 which produces less volatility then SPX .
Based on my Research using the BLOOMBERG TERMINAL; The fundamentals are strong and projections for earnings this JULY. The company will most likely beat earnings again. ANR (Analyst Recommendations) Based on this function, the 12 month TARGET PRICE is $335. There is 20 BUYS , 4 HOLDS, and 0 SELLS. Every analyst in the system has Target Prices higher than $300 and companies include but are not limited to Wells Fargo, Morning star, RBC Capital Markets, Cowen, Wolfe Research, etc.
INSIDER PURCHASE:
Norwood Felicia F ; Exec VP & President made a purchase of common stock on 7/2/2019. She bought 176 shares @ $280.66 bringing her to a total of 3,843 shares. The report (SEC FORM 4) was released to the public on 7/5/2019.
Tags: Anthem, ANTM, TSLA, APPL, GOO, BTC, LTC, Bitcoin, Blue Cross
USD is going to rise for 1-3 monthsfrom the pass 10 years, there is a unidirectional movement of the currency start in mid-Apr. either up or down for 1-3 months.
At this moment, DXY show a impulse leg going up, so the assumption is DXY go up for 1-3 monts to test 100.
according to EPSR report, money is flowing into US equity market, and selling European stock is most crowded trade. so there should be inflow of USD and fueling USD rising.
Bitcoin short term elliot wave analysisDrove Elliot wave count on 4 hourly. We are trending up in short term and if we continue to retrace to 0.382-0.5 Fib on each wave, this is how it would look like.
I believe 4400$ is imminent in short term.
If you want to know my take on monthly BTC price action check my previous post!
Long EURGBP Price have shown a significant pullback to test an important area around 0.88195. Medium term; market is in a uptrend with a possibility for it to continue its trend up to test the 1.272 Fib level. Kept S/L relatively close to the support. A break of the 0.88575 level will clearly support the direction of this trade. Needless to say, fundamentals and news related to Brexit may drive the volatility for this pair.
Buy ALDR on bullish closeALDR was recently upgraded by zacks to a rank of 2 (buy). ALDR is in the healthcare sector which has been doing well over the past 6 months. It is currently making a nice move up with higher highs and higher lows ( Ascending triangle). There may be a couple more days of consolidation so I will wait for a bullish confirmation with some strong volume to support the move. There is some overhead resistance to look out for ( I have highlighted this are in red ). The risk reward ratio on this trade is gorgeous. Almost 1 to 4 . I will take some profits at 1 to 2 and let it ride the rest of the way while continuously tightening my stop loss.